Co-Diagnostics, Inc. (CODX)
| Market Cap | 10.27M |
| Revenue (ttm) | 507,892 |
| Net Income (ttm) | -32.18M |
| Shares Out | 60.89M |
| EPS (ttm) | -0.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,037,964 |
| Open | 0.1798 |
| Previous Close | 0.1807 |
| Day's Range | 0.1657 - 0.1800 |
| 52-Week Range | 0.1657 - 1.5500 |
| Beta | 1.26 |
| Analysts | Strong Buy |
| Price Target | 2.25 (+1,234.52%) |
| Earnings Date | Nov 13, 2025 |
About CODX
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus... [Read more]
Financial Performance
In 2024, Co-Diagnostics's revenue was $3.92 million, a decrease of -42.53% compared to the previous year's $6.81 million. Losses were -$37.64 million, 6.53% more than in 2023.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CODX stock is "Strong Buy." The 12-month stock price target is $2.25, which is an increase of 1,234.52% from the latest price.
News
Co-Diagnostics Announces Reverse Stock Split
SALT LAKE CITY, Dec. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of mo...
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
The Australian patent represents the first patent granted for the Company's new point-of-care testing platform SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-D...
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
SALT LAKE CITY , Dec. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...
Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation
SALT LAKE CITY , Dec. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025
SALT LAKE CITY , Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of mo...
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India
Ongoing Phase II preclinical study data for Co-Dx PCR MTB and HPV tests support advancement to clinical performance testing SALT LAKE CITY , Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq:...
Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health
SALT LAKE CITY , Nov. 20, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA
SALT LAKE CITY , Nov. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics, Inc. (CODX) Q3 2025 Earnings Call Transcript
Co-Diagnostics, Inc. ( CODX) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chairman & CEO Brian Brown - CFO & Compa...
Co-Diagnostics Reports Third Quarter 2025 Financial Results
SALT LAKE CITY , Nov. 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for t...
Co-Diagnostics, Inc. (CODX) Discusses Saudi Arabia Joint Venture, AI Initiatives and Diagnostics Technology Developments Transcript
Co-Diagnostics, Inc. ( CODX) Discusses Saudi Arabia Joint Venture, AI Initiatives and Diagnostics Technology Developments November 5, 2025 11:00 AM EST Company Participants Dwight Egan - Chairman & C...
Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd
SALT LAKE CITY , Nov. 5, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a patented platform for developing advanced molecular...
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform
Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx's existing and future AI initiatives SALT LAKE CITY , Nov. 3, 2025 /PRNewswire...
Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast
SALT LAKE CITY , Oct. 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, ...
Co-Diagnostics to Host Fireside Chat on November 5th with CEO, Dwight Egan, to Discuss Recently Announced Definitive Agreement in Saudi Arabia
SALT LAKE CITY , Oct. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics, Inc. Announces Closing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
SALT LAKE CITY , Oct. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
SALT LAKE CITY , Oct. 28, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics Executive Leadership Team to Attend Global Health Exhibition 2025 in Riyadh, Saudi Arabia
Conference attendance follows recent MOU announcement for a joint venture with a regional manufacturing and distribution company in the Kingdom of Saudi Arabia SALT LAKE CITY , Oct. 22, 2025 /PRNewswi...
Co-Diagnostics Announces Development of Proprietary Sample Prep Instrument for PoC Testing
New device has the potential to help empower decentralized PCR testing in nearly 30,000 primary health centers across India, advancing efforts to improve availability of life-saving TB diagnostics SAL...
Co-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit
SALT LAKE CITY , Oct. 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics, Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30
SALT LAKE CITY , Sept. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of ...
Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
SALT LAKE CITY , Sept. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of ...
Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
SALT LAKE CITY , Sept. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of ...
Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains
SALT LAKE CITY , Sept. 11, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of ...
Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit
SALT LAKE CITY , Sept. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of m...